Discover how neoadjuvant chemotherapy influences the safety and long-term success of immediate breast reconstruction post-mastectomy, reshaping the future of breast cancer treatment and recovery.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy.
Nogi et al., Breast Cancer 2024
<!– DOI: 10.1007/s12282-024-01570-w //–>
https://doi.org/10.1007/s12282-024-01570-w
This study delves into the contentious issue of immediate breast reconstruction (IBR) following neoadjuvant chemotherapy (NAC) in breast cancer treatment. Analyzing data from 4726 breast cancer cases, the research compares surgical and oncological outcomes between patients who underwent IBR with and without prior NAC. The findings reveal that NAC does not significantly increase postoperative complications, with 20.3% of NAC patients experiencing issues compared to 17.5% of non-NAC patients. Furthermore, while initial analysis showed a lower 5-year local recurrence-free survival rate in the NAC group (93.1%) versus the control group (97.1%), propensity score matching indicated no significant difference in survival outcomes between the two groups. This suggests that IBR after NAC is a viable option with an acceptable risk profile, challenging previous concerns about its safety and efficacy. This study contributes to the ongoing debate by providing evidence that supports the safety of combining NAC with IBR in breast cancer treatment.